Physician profile
Jodilyn Gingold
NPI 1578668307
$2,197.10
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,549 · 2020: $292 · 2022: $356.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $982.82 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $394.56 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $326.65 | 2019-2020 | |
| Amgen INC. | $237.20 | 2022 | |
| Philips North America LLC | $188.00 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $53.24 | 2019 | |
| Merck Sharp & Dohme LLC | $14.63 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jodilyn Gingold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.